Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

Spring starts with the time change, and while it's nice now to have hours of additional sunlight every day, losing that hour ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

Sales rose 11% to 9.895 billion euros on higher demand for its blockbuster anti-inflammatory drug Dupixent. Sales of Dupixent rose 20% to 3.48 billion euros, slightly up from analysts' expectations of ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...